Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jade Biosciences, Inc.AVTE · Entity 4757 | SEE REMARKS | July 31, 2024 | August 02, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jade Biosciences, Inc.
Report date July 31, 2024 · Filed August 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,252 |
Ending reported balance
After 2024-08-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-07-31 · Exercise / conversion · Acquired 11,454 · Balance 12,745 Row 2 · 2024-08-01 · Exercise / conversion · Acquired 1,507 · Balance 14,252 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2030-09-03 | Direct | 0 |
Reported balance
After 2024-07-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-07-31 · Exercise / conversion · Disposed 906 · Balance 0 F1: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2030-09-03 | Direct | 1,507 |
Reported balance
After 2024-07-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-07-31 · Exercise / conversion · Disposed 10,548 · Balance 1,507 F2: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2030-09-03 | Direct | 0 |
Reported balance
After 2024-08-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-08-01 · Exercise / conversion · Disposed 1,507 · Balance 0 F2: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
F2: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 22, 2023 Filed Nov 27, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 6,970 | $2.14 | $14,915.80 |
DisclosureSEC source: 0001415889-23-015509 · form4-11272023_061104.xml · nonDerivative · entry 2 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,673 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| November 22, 2023 Filed Nov 27, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 2,412 | $1.74 | $4,196.88 |
DisclosureSEC source: 0001415889-23-015509 · form4-11272023_061104.xml · nonDerivative · entry 1 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,703 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| September 07, 2023 Filed Sep 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-013130 · form4-09082023_060901.xml · derivative · entry 10 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 150,226 Underlying: Common Stock · 30 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F6 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| September 07, 2023 Filed Sep 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 30 | $15.01 | $450.30 |
DisclosureSEC source: 0001415889-23-013130 · form4-09082023_060901.xml · nonDerivative · entry 5 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,291 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| September 07, 2023 Filed Sep 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 30 | $2.14 | $64.20 |
DisclosureSEC source: 0001415889-23-013130 · form4-09082023_060901.xml · nonDerivative · entry 4 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,321 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| September 06, 2023 Filed Sep 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 500 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-013130 · form4-09082023_060901.xml · derivative · entry 9 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 150,256 Underlying: Common Stock · 500 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F6 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| September 06, 2023 Filed Sep 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,018 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-013130 · form4-09082023_060901.xml · derivative · entry 8 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,350 Underlying: Common Stock · 1,018 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F5 · derivative.exercise_date: A total of 48,882 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| September 06, 2023 Filed Sep 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,507 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-013130 · form4-09082023_060901.xml · derivative · entry 7 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,575 Underlying: Common Stock · 1,507 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F4 · derivative.exercise_date: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| September 06, 2023 Filed Sep 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 906 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-013130 · form4-09082023_060901.xml · derivative · entry 6 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,622 Underlying: Common Stock · 906 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F3 · derivative.exercise_date: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| September 06, 2023 Filed Sep 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 3,931 | $15.06 | $59,186.71 |
DisclosureSEC source: 0001415889-23-013130 · form4-09082023_060901.xml · nonDerivative · entry 3 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,291 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.29, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 06, 2023 Filed Sep 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 1,518 | $2.14 | $3,248.52 |
DisclosureSEC source: 0001415889-23-013130 · form4-09082023_060901.xml · nonDerivative · entry 2 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,222 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| September 06, 2023 Filed Sep 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 2,413 | $1.74 | $4,198.62 |
DisclosureSEC source: 0001415889-23-013130 · form4-09082023_060901.xml · nonDerivative · entry 1 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,704 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| August 07, 2023 Filed Aug 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,853 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-011986 · form4-08092023_060801.xml · derivative · entry 8 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 150,756 Underlying: Common Stock · 6,853 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F7 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| August 07, 2023 Filed Aug 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,018 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-011986 · form4-08092023_060801.xml · derivative · entry 7 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,368 Underlying: Common Stock · 1,018 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F6 · derivative.exercise_date: A total of 48,882 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| August 07, 2023 Filed Aug 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,507 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-011986 · form4-08092023_060801.xml · derivative · entry 6 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,082 Underlying: Common Stock · 1,507 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F5 · derivative.exercise_date: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| August 07, 2023 Filed Aug 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 905 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-011986 · form4-08092023_060801.xml · derivative · entry 5 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,528 Underlying: Common Stock · 905 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F4 · derivative.exercise_date: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| August 07, 2023 Filed Aug 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 541 | $16.25 | $8,788.60 |
DisclosureSEC source: 0001415889-23-011986 · form4-08092023_060801.xml · nonDerivative · entry 4 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,291 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.175 to $16.470, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 07, 2023 Filed Aug 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 9,742 | $15.48 | $150,791.55 |
DisclosureSEC source: 0001415889-23-011986 · form4-08092023_060801.xml · nonDerivative · entry 3 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,832 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.17 to $16.17, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 07, 2023 Filed Aug 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 7,871 | $2.14 | $16,843.94 |
DisclosureSEC source: 0001415889-23-011986 · form4-08092023_060801.xml · nonDerivative · entry 2 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,574 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| August 07, 2023 Filed Aug 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 2,412 | $1.74 | $4,196.88 |
DisclosureSEC source: 0001415889-23-011986 · form4-08092023_060801.xml · nonDerivative · entry 1 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,703 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| July 06, 2023 Filed Jul 7, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,852 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-010966 · form4-07072023_060704.xml · derivative · entry 7 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,609 Underlying: Common Stock · 6,852 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F6 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| July 06, 2023 Filed Jul 7, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,019 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-010966 · form4-07072023_060704.xml · derivative · entry 6 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,386 Underlying: Common Stock · 1,019 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F5 · derivative.exercise_date: A total of 48,882 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| July 06, 2023 Filed Jul 7, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,506 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-010966 · form4-07072023_060704.xml · derivative · entry 5 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,589 Underlying: Common Stock · 1,506 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F4 · derivative.exercise_date: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| July 06, 2023 Filed Jul 7, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 906 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-010966 · form4-07072023_060704.xml · derivative · entry 4 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,433 Underlying: Common Stock · 906 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F3 · derivative.exercise_date: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| July 06, 2023 Filed Jul 7, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 10,283 | $16.66 | $171,283.93 |
DisclosureSEC source: 0001415889-23-010966 · form4-07072023_060704.xml · nonDerivative · entry 3 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,291 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.31 to $17.225, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 06, 2023 Filed Jul 7, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 7,871 | $2.14 | $16,843.94 |
DisclosureSEC source: 0001415889-23-010966 · form4-07072023_060704.xml · nonDerivative · entry 2 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,574 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| July 06, 2023 Filed Jul 7, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 2,412 | $1.74 | $4,196.88 |
DisclosureSEC source: 0001415889-23-010966 · form4-07072023_060704.xml · nonDerivative · entry 1 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,703 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,853 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-009448 · form4-06082023_060620.xml · derivative · entry 8 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 164,461 Underlying: Common Stock · 6,853 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F6 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,018 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-009448 · form4-06082023_060620.xml · derivative · entry 7 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,405 Underlying: Common Stock · 1,018 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F5 · derivative.exercise_date: A total of 48,882 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,507 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-009448 · form4-06082023_060620.xml · derivative · entry 6 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,095 Underlying: Common Stock · 1,507 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F4 · derivative.exercise_date: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 905 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-009448 · form4-06082023_060620.xml · derivative · entry 5 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,339 Underlying: Common Stock · 905 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F3 · derivative.exercise_date: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 15 | $16.98 | $254.63 |
DisclosureSEC source: 0001415889-23-009448 · form4-06082023_060620.xml · nonDerivative · entry 4 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,291 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 10,268 | $16.28 | $167,160.99 |
DisclosureSEC source: 0001415889-23-009448 · form4-06082023_060620.xml · nonDerivative · entry 3 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,306 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.84 to $16.82, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 7,871 | $2.14 | $16,843.94 |
DisclosureSEC source: 0001415889-23-009448 · form4-06082023_060620.xml · nonDerivative · entry 2 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,574 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 2,412 | $1.74 | $4,196.88 |
DisclosureSEC source: 0001415889-23-009448 · form4-06082023_060620.xml · nonDerivative · entry 1 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,703 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| May 08, 2023 Filed May 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,853 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-007686 · form4-05092023_060505.xml · derivative · entry 8 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 171,314 Underlying: Common Stock · 6,853 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F8 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| May 08, 2023 Filed May 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,018 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-007686 · form4-05092023_060505.xml · derivative · entry 7 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,423 Underlying: Common Stock · 1,018 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F7 · derivative.exercise_date: A total of 48,882 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| May 08, 2023 Filed May 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,507 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-007686 · form4-05092023_060505.xml · derivative · entry 6 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,602 Underlying: Common Stock · 1,507 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F6 · derivative.exercise_date: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| May 08, 2023 Filed May 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 906 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-007686 · form4-05092023_060505.xml · derivative · entry 5 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,244 Underlying: Common Stock · 906 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F5 · derivative.exercise_date: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| May 08, 2023 Filed May 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 1,599 | $22.74 | $36,354.54 |
DisclosureSEC source: 0001415889-23-007686 · form4-05092023_060505.xml · nonDerivative · entry 4 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,291 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.15 to $23.12, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| May 08, 2023 Filed May 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 8,685 | $21.62 | $187,805.31 |
DisclosureSEC source: 0001415889-23-007686 · form4-05092023_060505.xml · nonDerivative · entry 3 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,890 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.12 to $22.10, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| May 08, 2023 Filed May 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 7,871 | $2.14 | $16,843.94 |
DisclosureSEC source: 0001415889-23-007686 · form4-05092023_060505.xml · nonDerivative · entry 2 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,575 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| May 08, 2023 Filed May 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 2,413 | $1.74 | $4,198.62 |
DisclosureSEC source: 0001415889-23-007686 · form4-05092023_060505.xml · nonDerivative · entry 1 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,704 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F2 · balance_after: Includes 1,291 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on April 30, 2023 in a transaction that is exempt under Rule 16b-3(c) and 16b-3(d). Read SEC document |
| April 06, 2023 Filed Apr 7, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,852 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-006377 · form4-04072023_060403.xml · derivative · entry 7 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,167 Underlying: Common Stock · 6,852 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F6 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| April 06, 2023 Filed Apr 7, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,019 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-006377 · form4-04072023_060403.xml · derivative · entry 6 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,441 Underlying: Common Stock · 1,019 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F5 · derivative.exercise_date: A total of 48,882 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| April 06, 2023 Filed Apr 7, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,507 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-006377 · form4-04072023_060403.xml · derivative · entry 5 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,109 Underlying: Common Stock · 1,507 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F4 · derivative.exercise_date: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| April 06, 2023 Filed Apr 7, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 905 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-006377 · form4-04072023_060403.xml · derivative · entry 4 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,150 Underlying: Common Stock · 905 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F3 · derivative.exercise_date: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| April 06, 2023 Filed Apr 7, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 10,283 | $18.17 | $186,828.74 |
DisclosureSEC source: 0001415889-23-006377 · form4-04072023_060403.xml · nonDerivative · entry 3 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.785 to $18.58, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 06, 2023 Filed Apr 7, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 7,871 | $2.14 | $16,843.94 |
DisclosureSEC source: 0001415889-23-006377 · form4-04072023_060403.xml · nonDerivative · entry 2 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,283 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| April 06, 2023 Filed Apr 7, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 2,412 | $1.74 | $4,196.88 |
DisclosureSEC source: 0001415889-23-006377 · form4-04072023_060403.xml · nonDerivative · entry 1 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,412 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.